Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Karin Avila is active.

Publication


Featured researches published by Karin Avila.


Annals of Surgery | 2011

Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial.

Julio Garcia-Aguilar; David D. Smith; Karin Avila; Emily K. Bergsland; Peiguo Chu; Richard M. Krieg

Objective:To determine whether extending the interval between chemoradiation (CRT) and surgery, and administering additional chemotherapy during the waiting period has an impact on tumor response, CRT-related toxicity and surgical complications in patients with advanced rectal cancer. Background:Locally advanced rectal cancer is usually treated with preoperative CRT followed by surgery approximately 6 weeks later. The Timing of Rectal Cancer Response to Chemoradiation Consortium designed a prospective, multicenter, Phase II clinical trial to investigate extending the interval between CRT and surgery, and administering additional chemotherapy during the waiting period. Here, we present preliminary results of this trial, reporting the tumor response, CRT-related toxicity and surgical complications. Methods:Stage II and III rectal cancer patients were treated concurrently with 5-Fluorouracil (FU) and radiation for 5 to 6 weeks. Patients in study group (SG) 1 underwent total mesorectal excision (TME) 6 weeks later. Patients in SG2 with evidence of a clinical response 4 weeks after CRT received 2 cycles of modified FOLFOX-6 (mFOLFOX-6) followed by TME 3 to 5 weeks later. Tumor response, CRT-related toxicity and surgical complications were recorded. Results:One hundred and forty-four patients were accrued. One hundred and thirty-six (66, SG1; 70, SG2) were evaluated for CRT-related toxicity. One hundred and twenty-seven (60, SG1; 67, SG2) were assessed for tumor response and surgical complications. A similar proportion of patients completed CRT per protocol in both SGs, but the cumulative dose of sensitizing 5-FU and radiation was higher in SG2. CRT-related toxicity was comparable between SGs. Average time from CRT-to-surgery was 6 (SG1) and 11 weeks (SG2). Pathologic complete response (pCR) was 18% (SG1) and 25% (SG2). Postoperative complications were similar between SGs. Conclusions:Intense neoadjuvant therapy consisting of CRT followed by additional chemotherapy (mFOLFOX-6), and delaying surgery may result in a modest increase in pCR rate without increasing complications in patients undergoing TME for locally advanced rectal cancer.


Genes, Chromosomes and Cancer | 2016

Integrated genomic profiling identifies microRNA-92a regulation of IQGAP2 in locally advanced rectal cancer.

Raphael Pelossof; Oliver S Chow; Lauren Fairchild; J. Joshua Smith; Manu Setty; Chin-Tung Chen; Zhenbin Chen; Fumiko Egawa; Karin Avila; Christina S. Leslie; Julio Garcia-Aguilar

Locally advanced rectal cancer (LARC) is treated with chemoradiation prior to surgical excision, leaving residual tumors altered or completely absent. Integrating layers of genomic profiling might identify regulatory pathways relevant to rectal tumorigenesis and inform therapeutic decisions and further research. We utilized formalin‐fixed, paraffin‐embedded pre‐treatment LARC biopsies (n=138) and compared copy number, mRNA, and miRNA expression with matched normal rectal mucosa. An integrative model was used to predict regulatory interactions to explain gene expression changes. These predictions were evaluated in vitro using multiple colorectal cancer cell lines. The Cancer Genome Atlas (TCGA) was also used as an external cohort to validate our genomic profiling and predictions. We found differentially expressed mRNAs and miRNAs that characterize LARC. Our integrative model predicted the upregulation of miR‐92a, miR‐182, and miR‐221 expression to be associated with downregulation of their target genes after adjusting for the effect of copy number alterations. Cell line studies using miR‐92a mimics and inhibitors demonstrate that miR‐92a expression regulates IQGAP2 expression. We show that endogenous miR‐92a expression is inversely associated with endogenous KLF4 expression in multiple cell lines, and that this relationship is also present in rectal cancers of TCGA. Our integrative model predicted regulators of gene expression change in LARC using pre‐treatment FFPE tissues. Our methodology implicated multiple regulatory interactions, some of which are corroborated by independent lines of study, while others indicate new opportunities for investigation.


BMC Cancer | 2015

Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management

J. Joshua Smith; Oliver S Chow; Marc J. Gollub; Garrett M. Nash; Larissa K. Temple; Martin R. Weiser; Jose G. Guillem; Philip B. Paty; Karin Avila; Julio Garcia-Aguilar


Annals of Surgical Oncology | 2016

KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy.

Oliver S Chow; Deborah Kuk; Metin Keskin; J. Joshua Smith; Niedzica Camacho; Raphael Pelossof; Chin-Tung Chen; Zhenbin Chen; Karin Avila; Martin R. Weiser; Michael F. Berger; Sujata Patil; Emily K. Bergsland; Julio Garcia-Aguilar


Journal of Clinical Oncology | 2011

Impact of neoadjuvant chemotherapy following chemoradiation on tumor response, adverse events, and surgical complications in patients with advanced rectal cancer treated with TME.

Julio Garcia-Aguilar; J. Marcet; T. Coutsoftides; P. Cataldo; Alessandro Fichera; L. E. Smith; S. Oommen; Steven R. Hunt; Daniel O. Herzig; D. Dietz; Madhulika G. Varma; C. A. Ternent; Michael J. Stamos; Karin Avila; David D. Smith


Journal of Clinical Oncology | 2017

Institutional variation in the thoroughness of pathologic assessment and pathologic complete response rates for locally advanced rectal cancers treated with neoadjuvant chemoradiation.

Oliver S Chow; Sujata Patil; Metin Keskin; Jesse J. Smith; Maria Widmar; David D. Smith; Karin Avila; Jinru Shia; Peiguo Chu; Julio Garcia-Aguilar


/data/revues/14702045/unassign/S1470204515000042/ | 2015

Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial

Julio Garcia-Aguilar; Oliver S Chow; David D. Smith; Jorge Marcet; Peter A. Cataldo; Madhulika G. Varma; Anjali S. Kumar; Samuel Oommen; Theodore Coutsoftides; Steven R. Hunt; Michael J. Stamos; Charles A. Ternent; Daniel O. Herzig; Alessandro Fichera; Blase N. Polite; David W. Dietz; Sujata Patil; Karin Avila


Journal of Clinical Oncology | 2013

Gene expression profiles of rectal cancers with mutant or wild-type Kras.

Julio Garcia-Aguilar; Zhenbin Chen; Charles Warden; Karin Avila; Ning Zhou; Yate-Ching Yuan; Ching-Tung Chen; Martin R. Weiser


Journal of Clinical Oncology | 2013

Marker detection in rectal cancer chemoradiation response using an exhaustive combinatorics approach.

David D. Smith; Karin Avila; Zhenbin Chen; Wenyan Li; Julio Garcia-Aguilar


International Journal of Radiation Oncology Biology Physics | 2013

Phase 2 Timing of Rectal Cancer Response to Chemoradiation: Analysis of Radiation Therapy (RT)

Charles R. Thomas; Julio Garcia-Aguilar; Yiyi Chen; Karin Avila; Richard Krieg; Emily K. Bergsland; P. Chu; David D. Smith; David A. Rothenberger; J. Hwang

Collaboration


Dive into the Karin Avila's collaboration.

Top Co-Authors

Avatar

Julio Garcia-Aguilar

Memorial Sloan Kettering Cancer Center

View shared research outputs
Top Co-Authors

Avatar

David D. Smith

City of Hope National Medical Center

View shared research outputs
Top Co-Authors

Avatar

Oliver S Chow

Memorial Sloan Kettering Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Zhenbin Chen

City of Hope National Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

J. Joshua Smith

Memorial Sloan Kettering Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Martin R. Weiser

Memorial Sloan Kettering Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Sujata Patil

Memorial Sloan Kettering Cancer Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Chin-Tung Chen

Memorial Sloan Kettering Cancer Center

View shared research outputs
Researchain Logo
Decentralizing Knowledge